Evaluating the Khorana score in advanced EGFR-mutated NSCLC patients receiving first-line osimertinib.

Abstract

Listen

Translate article

e20634 Background: Venous thromboembolism (VTE) poses a significant risk in patients with non-small cell lung cancer (NSCLC), particularly those with driver mutations, such as in the Epidermal Growth Factor Receptor (EGFR). While the Khorana Score is commonly used to predict VTE risk in general oncology patients, its relevance in genetically defined subgroups, such as EGFR-mutated NSCLC patients, remains unclear. Methods: This retrospective study evaluated the correlation between the Khorana Score and VTE incidence in 47 advanced EGFR-mutated NSCLC patients receiving first-line osimertinib at the Inova Schar Cancer Institute. Baseline demographics and Khorana Score components, including platelet count, white blood cell count, body mass index, hemoglobin, and erythropoietin stimulating agent use, were recorded, with VTE incidence as the primary outcome. Results: VTE was observed in 19.1% of patients, but the Khorana Score did not significantly correlate with VTE development. Median progression-free survival (PFS) was 13.87 months in the VTE group compared to 9.9 months in those without VTE. Conclusions: Our findings suggest that the Khorana Score may not be a reliable predictor of VTE risk in EGFR-mutated NSCLC patients treated with osimertinib, likely due to its design for a more heterogeneous cancer population. Further research is warranted to develop tailored VTE risk models for this distinct patient subgroup.